Life Science Compliance Update

February

2017

February 2017: Life Science Compliance Update

Written by , Posted in February 2017 LSC Update, This Month in Compliance

The full text of the entire issue is now available to our subscribers. If you are a subscriber please log in now. You may also buy this issue by clicking on the button below.


   or   

February 2017 LSCU Cover

Issue Summary

This month we decided to look at both the compliance trends for 2017, as well as some of the “hot topics.” These hot topics include Patient Assistance Programs, Pharmaceutical Price Hikes and the new French anti-corruption law. We round out our coverage with the year-end enforcement highlights from the DOJ, OIG and FDA.


Feature Article

Arrow

Avoiding the Patient Assistance Program Spotlight
Kristin Rand, JD, MS, Compliance Officer, Seattle Genetics
Abstract

Issue Articles

Arrow

Product Price Hikes – When Business and Compliance Collide
Mark Scallon, Partner, FRA Life Sciences and Derek Patterson, Principal, FRA
Abstract

Arrow

Anti-corruption: all roads lead to enforcement
Caroline Franco, Amy Greenstein, Darren Jones & Veronique Monjardet
Abstract

Arrow

2017 Trending Towards a Banner Year for Industry Compliance
Robert N. Wilkey, Esq., Staff Writer for Life Science Compliance Update
Abstract

Arrow

Are the Safe Harbors Still Safe? – OIG Issues Final Rule
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update
Abstract

Arrow

Valeant and Philidor Controversy Comes to a Head
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update
Abstract

Arrow

FDA’s Meeting on Promotion – Can We Glimpse the Future?
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update
Abstract

Arrow

Antitrust and Generic Drugs – A Rare Combination
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update
Abstract

Menu Title